Instalab
logoInstalab

4q25 AF Risk Genotype (rs2200733)

Blood Test
Explore an inherited tendency toward irregular heart rhythm that may help explain your family history.
4.9 (4,409 reviews)
Tested by Quest Diagnostics
Physician-reviewed results
How it works
Order from Instalab
No prescription or your own doctor's order needed
Collect your sample
At home or at 2,000+ patient service centers
Get results
Explained with clear next steps, no medical jargon

Should you take a 4q25 AF Risk Genotype (rs2200733) test?

This test is most useful if any of these apply to you.

Living With a Family History of Early AF
This common variant may add context to your family history, but it doesn't identify every inherited cause of AF.
Exploring Your Inherited Heart Risk
Learn about one established genetic association while recognizing that its value for guiding preventive care remains unproven.
Living With AF That Started Young
The result offers inherited-risk information; early AF may also warrant evaluation for rare heart conditions.
Weighing Ablation or Cardioversion
Some studies link this variant to recurrence, but its value for choosing treatment or follow-up remains unproven.

About 4q25 AF Risk Genotype (rs2200733)

Atrial fibrillation (AF) is the most common sustained heart rhythm disorder. It can cause palpitations or go unnoticed, sometimes until a stroke occurs. Inherited differences contribute to its development, and the chromosome 4q25 region has one of the strongest and most consistently replicated genetic associations with AF.

This test reads one common variant in that region. Its association with AF is well established, but using this single result to choose screening or treatment remains exploratory. It adds information about inherited susceptibility without providing a diagnosis or a reliable estimate of your personal lifetime risk.

A One-Letter Difference Near PITX2

The result identifies the DNA letters at rs2200733. The label 4q25 describes its location on the long arm of chromosome 4. The two versions are C and T, with T associated with higher AF risk. You inherit one copy from each parent, so the result is CC, CT, or TT.

The variant sits between genes and doesn't alter a protein's sequence. Nearby PITX2 helps control heart development and electrical function. Mouse experiments link Pitx2c to formation of the muscle surrounding the pulmonary veins. Electrical activity from that muscle commonly triggers AF.

The biological explanation is still being worked out. A 2026 study found that the rs2200733 risk version was associated with increased activity of the PITX2C form of the gene in human atrial tissue. Experiments on isolated human heart cells also found differences in calcium handling and electrical activity. These findings don't support a simple account in which the T version always turns PITX2 down.

In a separate study of people undergoing AF ablation, carriers had more uneven electrical conduction when their atria were mapped. These observations help explain why the region interests researchers, but they don't establish what happens in every carrier's heart.

Atrial Fibrillation Risk

The original discovery study found about 1.7 times the odds of AF per T copy in European samples. A later meta-analysis pooled seven studies and about 83,000 people. After adjustment for other risk factors, carriers in the five European studies had about 1.9 times the odds of AF compared with non-carriers, while the two Chinese studies pooled to about 1.5. The individual studies disagreed considerably. An increase in odds isn't the same as an increase in your absolute probability of developing AF.

Estimates vary with the population and study design. One meta-analysis found about 1.4 times the odds in community cohorts, compared with about 1.8 in case-control studies that recruited people with and without AF. These differences are one reason a single published figure shouldn't be turned into a personal risk forecast.

Age, blood pressure, weight, diabetes, heart disease, and other genetic variants also contribute. The T version can be present in someone who never develops AF, while someone with CC can still develop it. The result doesn't show whether an irregular rhythm is happening now.

AF That Starts Young

Some studies found a stronger association in AF occurring without recognized heart disease or other usual risk factors. Older papers often called this lone AF, although definitions varied and the term is now discouraged.

In a Chinese Han study, the T version was associated with about 2.4 times the odds of lone AF, compared with about 1.6 times the odds of other AF. A Danish study also found an association in people whose AF began before age 40. These findings support a genetic contribution to early AF; they don't show that screening healthy younger adults for this single variant improves outcomes.

Families With Rare Rhythm Variants

Rare variants in genes such as SCN5A and KCNQ1 can contribute to inherited rhythm disorders. In a small study of 11 families, researchers examined rs2200733 together with another common 4q25 variant and rare variants in heart-related genes. The combination was associated with which relatives had AF, suggesting that common variants can modify the effects of rarer ones. This test doesn't examine those rare variants.

Stroke

AF can allow blood clots to form in the heart and travel to the brain. An ischemic stroke occurs when blood flow to the brain is blocked. In European studies, each rs2200733 T copy was associated with about a quarter higher odds of ischemic stroke. The association was stronger for strokes attributed to a clot from the heart, with about half higher odds.

A Chinese Han study did not detect an association with ischemic stroke. Undetected AF is a plausible explanation for part of the European stroke association, but these studies don't establish that testing this variant and acting on the result prevents strokes.

Atrial Flutter

Atrial flutter is another rhythm disorder. Its typical form involves a fast electrical circuit in the right atrium. Italian and US studies linked rs2200733 to flutter as well as AF. The US study did not detect a difference in subsequent AF after typical flutter ablation between carriers and non-carriers.

Recurrence After Rhythm Treatment

Several observational studies have linked rs2200733 to recurrence after AF treatment. Catheter ablation treats tissue involved in abnormal electrical signals. Electrical cardioversion uses a timed shock to restore a normal rhythm.

Who Was StudiedWhat Was ComparedWhat They Found
991 adults undergoing AF ablation at three centersCT or TT compared with CCCarriers had about a 30 percent higher rate of recurrent atrial rhythm disturbances during one-year follow-up.
311 adults undergoing 378 AF ablation procedures at one centerCT and TT compared with CCEstimated time free of recurrent atrial rhythm disturbances was about a fifth shorter with CT and about two fifths shorter with TT.
162 adults whose normal rhythm was restored by cardioversionTT compared with CCThe reported median time to AF recurrence was 7 days with TT and 64 days with CC.

The ablation outcomes included AF and other atrial rhythm disturbances. Results have not been consistent across populations: a Korean study found no association between these common AF variants and ablation success. These studies have not established that choosing a procedure, drug, or follow-up schedule based on rs2200733 improves your outcome.

Association and Individual Prediction

The frequency of T and its estimated effect differ across ancestry groups. A result that is common in one population may be much less common in another, and an estimate from a European study may not transfer directly to your background.

The 4q25 region contains several separate risk signals. In one study combining three signals, the highest-risk combination was associated with about six times the AF risk of the most common combination. That comparison involved several DNA positions, so it cannot be applied to a TT result from this test.

Scores combining variants across the genome can provide more information than a single position. In a study of adults with symptoms or clinical risk factors, those in the highest fifth of a 12-variant score had about three times the odds of newly detected AF compared with the lowest fifth. AF was detected with ECGs or ambulatory monitoring.

Larger genetic scores have added information to clinical risk factors and NT-proBNP in cardiovascular disease cohorts. NT-proBNP is a blood marker of strain on the heart. A separate research model based on blood proteins predicted AF better than the genetic model it was compared with, and adding genetics did not improve its performance. Neither result validates this single variant as a stand-alone screening tool.

When Results Can Be Misleading

  • Limited coverage: CC means you don't carry T at this position. It doesn't rule out other common AF risk variants, rare inherited rhythm disorders, or AF itself.
  • Ancestry: variant frequencies and the relationship between nearby DNA variants differ across populations. Risk estimates need to be interpreted in the population in which they were studied.
  • Uncertain findings on broader panels: some genetic panels identify variants whose effects on health are unknown. These are called variants of uncertain significance and should not determine treatment or predictive testing of relatives. They are different from the established population-level association at rs2200733.
  • Sample source: tumor DNA can contain changes acquired during life. After a donor stem-cell transplant, blood DNA can reflect the donor's genotype. These situations require specialist selection of a suitable sample for inherited testing.
  • Conflicting reports: consumer DNA reports and clinical tests can differ in accuracy or interpretation. A disagreement that would affect care warrants confirmation on a new clinical sample using a different validated method.

A One-Time Result

Your inherited genotype is permanent, so routine repeat testing has no role. Its value is as background information alongside your family history and heart health. Blood pressure, symptoms, and heart rhythm can change over time; the timing of those checks follows your clinical risk, because this variant alone doesn't establish a monitoring schedule.

Frequently Asked Questions

Panels containing 4q25 AF Risk Genotype (rs2200733)

4q25 AF Risk Genotype (rs2200733) is included in these pre-built panels.

References

24 studies
  1. Daniel Fannar Gudbjartsson, Davíð O. Arnar, Anna Helgadóttir, Sólveig Grétarsdóttir, Hilma Hólm, Et Al.Nature2007
  2. Sanghamitra Mohanty, Pasquale Santangeli, Rong Bai, Luigi Di Biase, Prasant Kumar Mohanty, Agnes Pump, Andrea NataleJournal of Cardiovascular Electrophysiology2013
  3. Albert Ferrán, Josep Maria Alegret, Isaac Subirana, Gerard Aragonès, Carla Lluís-ganella, Et Al.Revista Española De Cardiología (English Edition)2014
  4. Mathilda T. M. Mommersteeg, Nigel a. Brown, Owen W. J. Prall, Corrie De Gier-de Vries, Richard P. Harvey, Antoon F. M. Moorman, Vincent M. ChristoffelsCirculation Research2007
  5. Verónica Jiménez-sábado, Carmen Tarifa, Oliver B. Vad, Sergi Casabella-ramón, Gabriel Manzano-reche, Et Al.Cardiovascular Research2026

4q25 AF Risk Genotype (rs2200733) Testing Option

4q25-AF Risk Genotype

$715

Understand part of your inherited tendency toward an irregular heart rhythm, even before symptoms appear.

Includes 2 biomarkers:
4q25 AF Risk Genotype (rs2200733)4q25 AF Risk Genotype (rs10033464)
FSA/HSA eligible
No Rx needed
HIPAA compliant